

National Imaging Associates, Inc.	
Clinical guideline: CT CORONARY ANGIOGRAPHY (CCTA)	Original Date: October 2009
CPT Codes: 75574	Last Revised Date: February April 2023February 2022
Guideline Number: NIA_CG_062	Implementation Date: January 2024 3

GENERAL INFORMATION

- It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.
- Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.

GENERAL INFORMATION

~~It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.~~

INDICATIONS FOR CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY (CCTA)¹⁻⁴

Evaluation in Suspected Coronary Artery Disease (CAD)⁵⁻⁸

- Intermediate and high pretest probability patients⁹
- Low pretest probability patients should be considered for exercise treadmill test (ETT) unless other criteria for CCTA are met
- Symptomatic patients with prior PCI (stents > 3mm) or CABG history
-
- Exercise ECG stress test with intermediate Duke Treadmill (- 10 to + 4)

*National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

- Equivocal, borderline, or discordant stress imaging evaluation with continued symptoms concerning for CAD
- Repeat testing in patient with new or worsening symptoms since prior normal stress imaging^{3, 4}
- Asymptomatic patients without known CAD
 - Previously unevaluated ECG evidence of possible myocardial ischemia including ischemic ST segment or T wave abnormalities [\(see overview section\)](#)
 - Previously unevaluated pathologic Q waves [\(see overview section\)](#)
 - Previously unevaluated left bundle branch block
- Newly diagnosed clinical systolic heart failure ~~(ejection fraction [EF] < 50%) or diastolic heart failure, with reasonable suspicion of cardiac ischemia (prior events, risk factors), unless invasive coronary angiography is planned (SE diversion not required) without recent CAD evaluation, in the presence of angina or an anginal equivalent symptoms, as an alternative to invasive coronary arteriography.~~^{3, 4, 10-12}
- Before valve surgery or transcatheter intervention as an alternative to coronary angiography¹³⁻¹⁵
- To establish the etiology of mitral regurgitation¹⁵
- Evaluation of coronary anomaly or aneurysm¹⁶⁻¹⁹
 - Evaluation prior to planned repair
 - Evaluation due to change in clinical status and/or new concerning signs or symptoms
 - [Kawasaki disease and MIS-C follow up – for medium sized or greater aneurysms, periodic surveillance can be considered every 2-5 years. Once aneurysmal size has reduced to small aneurysms, surveillance can be performed every 3-5 years. No further surveillance once normalized.](#)²⁰
- Evaluation of coronary artery bypass grafts, to assess^{3, 21}:
 - Patency and location when invasive coronary arteriography was either nondiagnostic or not performed
 - Location prior to cardiac or another chest surgery

[Electrophysiologic Procedure Planning](#)

- [Evaluation of anatomy prior to radiofrequency ablation](#)

~~[Low probability patients will be directed to exercise stress test over CCTA unless other criteria for imaging studies are met.](#)~~

BACKGROUND

Coronary computed tomographic angiography (CCTA) is a noninvasive imaging study that uses intravenously administered contrast material and high-resolution, rapid imaging computed tomography (CT).^{22, 23}

Stable patients without known CAD fall into 2 categories^{1, 2, 4}:

- **Asymptomatic**, for whom global risk of CAD events can be determined from coronary risk factors, using calculators available online (see [Risk Calculators](#) in the Overview section).
- **Symptomatic**, for whom we estimate the pretest probability that their chest-related symptoms are due to clinically significant CAD.

Three Types of Chest Pain or Discomfort:

- **Typical Angina (Definite)** is defined as including **ALL 3** characteristics:
 - Substernal chest pain or discomfort with characteristic quality and duration
 - Provoked by exertion or emotional stress
 - Relieved by rest and/or nitroglycerin
- **Atypical Angina (Probable)** has only **2** of the above characteristics
- **Nonanginal Chest Pain/Discomfort** has only **0 - 1** of the above characteristics
- Once the type of chest pain has been established from the medical record, the Pretest Probability of significant CAD is estimated from the **Diamond Forrester Table** below, recognizing that additional coronary risk factors could increase pretest probability⁴:

Diamond Forrester Table

Age (Years)	Gender	Typical/Definite Angina Pectoris	Atypical/Probable Angina Pectoris	Nonanginal Chest Pain
≤ 39	Men	Intermediate	Intermediate	Low
	Women	Intermediate	Very low	Very low
40 – 49	Men	High	Intermediate	Intermediate
	Women	Intermediate	Low	Very low
50 – 59	Men	High	Intermediate	Intermediate
	Women	Intermediate	Intermediate	Low
≥ 60	Men	High	Intermediate	Intermediate
	Women	High	Intermediate	Intermediate

- **Very Low:** < 5% pretest probability of CAD
- **Low:** 5 - 10% pretest probability of CAD
- **Intermediate:** 10% - 90% pretest probability of CAD

- **High:** > 90% pretest probability of CAD

OVERVIEW

The 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain **has given** a Class 1 recommendation with level of evidence of A for patients with stable and acute chest pain, who have no known coronary artery disease (CAD).⁹

Patient selection and contraindications to CCTA must be considered and may be inappropriate for the following:

- Known history of severe and/or anaphylactic contrast reaction
- Inability to cooperate with scan acquisition and/or breath-hold instructions
- Pregnancy
- Clinical instability (e.g., acute myocardial infarction, decompensated heart failure, severe hypotension)
- Renal impairment as defined by local protocols
- Image quality depends on keeping HR optimally < 60 bpm, a regular rhythm, limited coronary calcification, stents > 3.0 mm in diameter, ≥ 5 second breath hold, and vessels requiring imaging ≥ 1.5 mm diameter.²⁴

Scenarios that can additionally support a CCTA over a regular exercise treadmill test in the low probability scenario²⁵

Inability to Exercise

- Physical limitations precluding ability to exercise for at least 3 full minutes of Bruce protocol
- The patient has limited functional capacity (< 4 METS) such as **ONE** of the following:
 - Unable to take care of their activities of daily living (ADLs) or ambulate
 - Unable to walk 2 blocks on level ground
 - Unable to climb 1 flight of stairs
 - Unable to vacuum, dust, do dishes, sweep, or carry a small grocery bag

Other Comorbidities

- Prior cardiac surgery (coronary artery bypass graft or valvular)
- Left ventricular ejection fraction ≤ 50%
- Severe chronic obstructive pulmonary disease (COPD) with pulmonary function test (PFT) documentation, severe shortness of breath on minimal exertion, or requirement of home oxygen during the day
- Poorly controlled hypertension, with systolic blood pressure (BP) > 180 or Diastolic BP > 120

ECG and Echo-Related Baseline Findings

- Pacemaker or implantable cardioverter defibrillator (ICD)
- Resting wall motion abnormalities on echocardiography
- Complete LBBB

Risk-Related

- Intermediate or high global risk in patients requiring type IC antiarrhythmic drugs
- Arrhythmia risk with exercise

ECG Stress Test Alone versus Stress Testing with Imaging

Prominent scenarios suitable for an ECG stress test **WITHOUT** imaging (i.e., exercise treadmill ECG test) require that the patient can exercise for at least 3 minutes of Bruce protocol with achievement of near maximal heart rate **AND** has an interpretable ECG for ischemia during exercise⁴:

- The (symptomatic) low pretest probability patient who can exercise and has an interpretable ECG⁴
- The patient who is under evaluation for exercise-induced arrhythmia
- The patient who requires an entrance stress test ECG for a cardiac rehab program or for an exercise prescription
- For the evaluation of syncope or presyncope during exertion²⁶

Duke Exercise ECG Treadmill Score²⁷

Calculates risk from ECG treadmill alone:

- The equation for calculating the Duke treadmill score (DTS) is: $DTS = \text{exercise time in minutes} - (5 \times \text{ST deviation in mm or } 0.1 \text{ mV increments}) - (4 \times \text{exercise angina score})$, with angina score being 0 = none, 1 = non-limiting, and 2 = exercise-limiting
- The score typically ranges from - 25 to + 15. These values correspond to low-risk (with a score of $\geq + 5$), intermediate risk (with scores ranging from - 10 to + 4), and high-risk (with a score of $\leq - 11$) categories

An uninterpretable baseline ECG includes¹:

- ST segment depression of 1 mm or more (not for non-specific ST - T wave changes)
- Ischemic looking T wave inversions of at least 2.5 mm
- LVH with repolarization abnormalities, WPW, a ventricular paced rhythm, or left bundle branch block
- Digitalis use with associated ST - T abnormalities
- Resting HR under 50 bpm on a beta blocker and an anticipated suboptimal workload

- Note: RBBB with less than 1 mm ST depression at rest may be suitable for ECG treadmill testing
- Previously unevaluated pathologic Q waves (in two contiguous leads) defined as the following:
 - > 40 ms (1 mm) wide
 - > 2 mm deep
 - > 25% of depth of QRS complex

Global Risk of Cardiovascular Disease

Global risk of CAD is defined as the probability of manifesting cardiovascular disease over the next 10 years and refers to **asymptomatic** patients without known cardiovascular disease. It should be determined using one of the risk calculators below. A high risk is considered greater than a 20% risk of a cardiovascular event over the ensuing 10 years.

-High global risk by itself generally lacks scientific support as an indication for stress imaging.⁵ There are rare exemptions, such as patients requiring IC antiarrhythmic drugs, who might require coronary risk stratification prior to initiation of the drug, when global risk is moderate or high.

- **CAD Risk—Low**
10 - year absolute coronary or cardiovascular risk less than 10%
- **CAD Risk—Moderate**
10 - year absolute coronary or cardiovascular risk between 10% and 20%
- **CAD Risk—High**
10 - year absolute coronary or cardiovascular risk of greater than 20%

Websites for Global Cardiovascular Risk Calculators*

Risk Calculator	Websites for Online Calculator
Framingham Cardiovascular Risk	https://reference.medscape.com/calculator/framingham-cardiovascular-disease-risk
Reynolds Risk Score Can use if no diabetes Unique for use of family history	http://www.reynoldsriskscore.org/
Pooled Cohort Equation	http://clincalc.com/Cardiology/ASCVD/PooledCohort.aspx?example
ACC/AHA Risk Calculator	http://tools.acc.org/ASCVD-Risk-Estimator/

MESA Risk Calculator With addition of Coronary Artery Calcium Score, for CAD-only risk	https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx
---	---

*Patients who have already manifested cardiovascular disease are already at high global risk and are not applicable to the calculators.²⁸⁻³²

Definitions of Coronary Artery Disease^{1, 2, 33-35}

- Percentage stenosis refers to the reduction in diameter stenosis when angiography is the method and can be estimated or measured using angiography or more accurately measured with intravascular ultrasound (IVUS).
- Coronary artery calcification is a marker of risk, as measured by Agatston score on coronary artery calcium imaging. It is not a diagnostic tool so much as it is a **risk stratification** tool. Its incorporation into global risk can be achieved by using the MESA risk calculator.
- Stenoses $\geq 70\%$ are considered obstructive coronary artery disease (also referred to as clinically significant), while stenoses $\leq 70\%$ are considered non-obstructive coronary artery disease.³³
- Ischemia-producing disease (also called hemodynamically or functionally significant disease, for which revascularization might be appropriate) generally implies at least one of the following:
 - Suggested by percentage diameter stenosis $\geq 70\%$ by angiography; intermediate lesions are 50 – 69%³⁶
 - For a left main artery, suggested by a percentage stenosis $\geq 50\%$ or minimum luminal cross-sectional area on IVUS ≤ 6 square mm^{1, 35, 37}
 - FFR (fractional flow reserve) ≤ 0.80 for a major vessel^{35, 37}
 - iFR (instantaneous wave-free ratio) ≤ 0.89 for a major vessel^{35, 38-40}
 - Demonstrable ischemic findings on stress testing (ECG or stress imaging), that are at least mild in degree
- A major vessel would be a coronary vessel that would be amenable to revascularization, if indicated. This assessment is made based on the diameter of the vessel and/or the extent of myocardial territory served by the vessel.
- FFR is the distal to proximal pressure ratio across a coronary lesion during maximal hyperemia induced by either intravenous or intracoronary adenosine. Less than or equal to 0.80 is considered a significant reduction in coronary flow.
- Newer technology that estimates FFR from CCTA images is covered under the separate NIA Guideline for FFR-CT.

Anginal Equivalent^{1, 26, 41}

Development of an anginal equivalent (e.g., shortness of breath, fatigue, or weakness) either with or without prior coronary revascularization should be based upon the documentation of reasons that symptoms other than chest discomfort are not due to other organ systems (e.g., dyspnea due to lung disease, fatigue due to anemia), by presentation of clinical data such as respiratory rate, oximetry, lung exam, etc. (as well as D-dimer, chest CT(A), and/or PFTs, when appropriate), and then incorporated into the evaluation of coronary artery disease as would chest discomfort. Syncope, per se, is not an anginal equivalent.

Abbreviations

ACS	Acute coronary syndrome
ADLs	Activities of daily living
CABG	Coronary artery bypass grafting surgery
CAD	Coronary artery disease
CCS	Coronary calcium score
CCTA	Coronary computed tomography angiography
CT(A)	Computed tomography (angiography)
COPD	Chronic obstructive pulmonary disease
DTS	Duke Treadmill Score
ECG	Electrocardiogram
EF	Ejection fraction
FFR	Fractional flow reserve
ICD	Implantable cardioverter-defibrillator
iFR	Instantaneous wave-free ratio or instant flow reserve
IVUS	Intravascular ultrasound
LBBB	Left bundle branch block
LVH	Left ventricular hypertrophy
MESA	Multi-Ethnic Study of Atherosclerosis
METS	Metabolic equivalents
MI	Myocardial infarction
MPI	Myocardial perfusion imaging
PCI	Percutaneous coronary intervention
PFT	Pulmonary function test
RBBB	Right bundle branch block
SE	Stress echocardiography
TTE	Transthoracic echocardiography
WPW	Wolff-Parkinson-White syndrome

POLICY HISTORY

Date	Summary
February 2023	<ul style="list-style-type: none"> Added Electrophysiology testing prior to ablation Added Kawasaki/MIS-C section on follow up Added statement about low pretest probability Added statement on clinical indications not addressed in this guideline
February 2023	Added Kawasaki/MIS-C section on follow up
February 2023	Added statement about low pretest probability
February 2022	<ul style="list-style-type: none"> Clarified “intermediate lesions are 50-69%” for ischemia-producing disease
January 2022	<p>{Off-cycle review}</p> <ul style="list-style-type: none"> Deleted the requirement for stress echocardiography. Changed to Intermediate and High probability chest pain patients now allowable as first line testing Intermediate DTS patients now allowable for CCTA Removed EF < 40%, keeping the existing EF < 50% systolic dysfunction, and adding symptomatic diastolic heart failure with no prior workup Added a paragraph explaining the changes, new guidelines of November 2021 with contraindications within the overview section Added section on when CCTA is preferred over ETT in low-risk patients Deleted the phrasing ‘scenarios that support MPI over SE’ as it would no longer apply here. Replaced with ‘Scenarios that can additionally support a CCTA over a regular exercise treadmill test in the low probability scenario’. Deleted statement that MPI may be supported over CCTA in Poorly controlled atrial fibrillation/ectopy Took out the word ‘intermediate’ in the phrase “The (symptomatic) low pretest probability patient who is able to exercise and has an interpretable ECG” Removed section on Coronary Artery calcium scoring
March 2021	<ul style="list-style-type: none"> Deleted: Appropriate exercise ECG stress test with low Duke Treadmill Score (≥ 5) and continued symptoms concerning for CAD Added: High pretest probability as an alternative to coronary angiography (can also do MPI)

	<ul style="list-style-type: none"> ● Removed statement about low Duke treadmill score and continuing symptoms
March 2020	<ul style="list-style-type: none"> ● Added general information section as Introduction which outlines requirements for documentation of pertinent office notes by a licensed clinician, and inclusion of laboratory testing and relevant imaging results for case review ● Added further details for imaging of coronary anomaly or aneurysm to include the following: <ul style="list-style-type: none"> ○ Evaluation prior to planned repair ○ Evaluation due to change in clinical status and/or new concerning signs or symptoms ● Added edits to the coronary artery disease definition section ● Updated and added references
July 2019	<ul style="list-style-type: none"> ● CCTA can be used as an alternative to coronary angiography in appropriate patients prior to valve surgery or transcatheter intervention ● Noted CMR is favored over CCTA in young patients for evaluation of coronary anomaly or aneurysm ● Global Risk of Cardiovascular Disease information expanded in background section for additional clarification

REFERENCES:

1. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. Dec 18 2012;126(25):e354-471. doi:10.1161/CIR.0b013e318277d6a0
2. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. Oct 2013;34(38):2949-3003. doi:10.1093/eurheartj/ehs296
3. Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. *J Am Coll Cardiol*. Nov 23 2010;56(22):1864-94. doi:10.1016/j.jacc.2010.07.005
4. Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. Feb 4 2014;63(4):380-406. doi:10.1016/j.jacc.2013.11.009
5. Cheng VY, Berman DS, Rozanski A, et al. Performance of the traditional age, sex, and angina typicality-based approach for estimating pretest probability of angiographically significant coronary artery disease in patients undergoing coronary computed tomographic angiography: results from the multinational coronary CT angiography evaluation for clinical outcomes: an international multicenter registry (CONFIRM). *Circulation*. Nov 29 2011;124(22):2423-32, 1-8. doi:10.1161/circulationaha.111.039255
6. Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. Apr 2 2015;372(14):1291-300. doi:10.1056/NEJMoa1415516

7. Fordyce CB, Newby DE, Douglas PS. Diagnostic Strategies for the Evaluation of Chest Pain: Clinical Implications From SCOT-HEART and PROMISE. *J Am Coll Cardiol*. Feb 23 2016;67(7):843-52. doi:10.1016/j.jacc.2015.11.055
8. Newby D, Williams M, Hunter A, et al. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. *Lancet*. Jun 13 2015;385(9985):2383-91. doi:10.1016/s0140-6736(15)60291-4
9. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. Nov 30 2021;78(22):e187-e285. doi:10.1016/j.jacc.2021.07.053
10. Patel MR, Bailey SR, Bonow RO, et al. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. May 29 2012;59(22):1995-2027. doi:10.1016/j.jacc.2012.03.003
11. Patel MR, White RD, Abbara S, et al. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. *J Am Coll Cardiol*. May 28 2013;61(21):2207-31. doi:10.1016/j.jacc.2013.02.005
12. Doherty JU, Kort S, Mehran R, et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. *J Nucl Cardiol*. Aug 2019;26(4):1392-1413. doi:10.1007/s12350-019-01751-7
13. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. Sep 21 2017;38(36):2739-2791. doi:10.1093/eurheartj/ehx391
14. Chaikriangkrai K, Jhun HY, Shantha GPS, et al. Diagnostic Accuracy of Coronary Computed Tomography Before Aortic Valve Replacement: Systematic Review and Meta-Analysis. *J Thorac Imaging*. Jul 2018;33(4):207-216. doi:10.1097/rti.0000000000000322
15. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American

- Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Jun 10 2014;63(22):e57-185. doi:10.1016/j.jacc.2014.02.536
16. Bluemke DA, Achenbach S, Budoff M, et al. Noninvasive coronary artery imaging: magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the american heart association committee on cardiovascular imaging and intervention of the council on cardiovascular radiology and intervention, and the councils on clinical cardiology and cardiovascular disease in the young. *Circulation*. Jul 29 2008;118(5):586-606. doi:10.1161/circulationaha.108.189695
 17. Gräni C, Buechel RR, Kaufmann PA, Kwong RY. Multimodality Imaging in Individuals With Anomalous Coronary Arteries. *JACC Cardiovasc Imaging*. Apr 2017;10(4):471-481. doi:10.1016/j.jcmg.2017.02.004
 18. Newburger JW, Takahashi M, Burns JC. Kawasaki Disease. *J Am Coll Cardiol*. Apr 12 2016;67(14):1738-49. doi:10.1016/j.jacc.2015.12.073
 19. Sachdeva R, Valente AM, Armstrong AK, et al. ACC/AHA/ASE/HRS/ISACHD/SCAI/SCCT/SCMR/SOPE 2020 Appropriate Use Criteria for Multimodality Imaging During the Follow-Up Care of Patients With Congenital Heart Disease: A Report of the American College of Cardiology Solution Set Oversight Committee and Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Pediatric Echocardiography. *J Am Coll Cardiol*. Feb 18 2020;75(6):657-703. doi:10.1016/j.jacc.2019.10.002
 20. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. *Circulation*. Apr 25 2017;135(17):e927-e999. doi:10.1161/cir.0000000000000484
 21. Eisenberg C, Hulten E, Bittencourt MS, Blankstein R. Use of CT angiography among patients with prior coronary artery bypass grafting surgery. *Cardiovasc Diagn Ther*. Feb 2017;7(1):102-105. doi:10.21037/cdt.2016.11.08
 22. Nakamura S, Kitagawa K, Goto Y, et al. Incremental Prognostic Value of Myocardial Blood Flow Quantified With Stress Dynamic Computed Tomography Perfusion Imaging. *JACC Cardiovasc Imaging*. Jul 2019;12(7 Pt 2):1379-1387. doi:10.1016/j.jcmg.2018.05.021
 23. Pontone G, Baggiano A, Andreini D, et al. Stress Computed Tomography Perfusion Versus Fractional Flow Reserve CT Derived in Suspected Coronary Artery Disease: The PERFECTION Study. *JACC Cardiovasc Imaging*. Aug 2019;12(8 Pt 1):1487-1497. doi:10.1016/j.jcmg.2018.08.023
 24. Abbara S, Blanke P, Maroules CD, et al. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: A report of the society of Cardiovascular Computed Tomography Guidelines Committee: Endorsed by the North American Society for Cardiovascular Imaging (NASCI). *J Cardiovasc Comput Tomogr*. Nov-Dec 2016;10(6):435-449. doi:10.1016/j.jcct.2016.10.002

25. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. *J Nucl Cardiol*. Jun 2016;23(3):606-39. doi:10.1007/s12350-015-0387-x
26. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. Aug 1 2017;70(5):620-663. doi:10.1016/j.jacc.2017.03.002
27. Mark DB, Hlatky MA, Harrell FE, Jr., Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. *Ann Intern Med*. Jun 1987;106(6):793-800. doi:10.7326/0003-4819-106-6-793
28. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. Feb 12 2008;117(6):743-53. doi:10.1161/circulationaha.107.699579
29. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. Sep 10 2019;74(10):e177-e232. doi:10.1016/j.jacc.2019.03.010
30. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Jul 1 2014;63(25 Pt B):2935-2959. doi:10.1016/j.jacc.2013.11.005
31. McClelland RL, Jorgensen NW, Budoff M, et al. 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). *J Am Coll Cardiol*. Oct 13 2015;66(15):1643-53. doi:10.1016/j.jacc.2015.08.035
32. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *Jama*. Feb 14 2007;297(6):611-9. doi:10.1001/jama.297.6.611
33. Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. May 2 2017;69(17):2212-2241. doi:10.1016/j.jacc.2017.02.001
34. Mintz G. IVUS in PCI Guidance. American College of Cardiology. Updated June 13, 2016. Accessed January 27, 2023. <https://www.acc.org/latest-in-cardiology/articles/2016/06/13/10/01/ivus-in-pci-guidance>

35. Lotfi A, Davies JE, Fearon WF, Grines CL, Kern MJ, Klein LW. Focused update of expert consensus statement: Use of invasive assessments of coronary physiology and structure: A position statement of the society of cardiac angiography and interventions. *Catheter Cardiovasc Interv.* Aug 1 2018;92(2):336-347. doi:10.1002/ccd.27672
36. Patel MR, Bailey SR, Bonow RO, et al. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, Society of Thoracic Surgeons. *J Thorac Cardiovasc Surg.* Jul 2012;144(1):39-71. doi:10.1016/j.jtcvs.2012.04.013
37. Mintz G. IVUS in PCI Guidance. American College of Cardiology. Updated June 13, 2016. Accessed October 22, 2021. <https://www.acc.org/latest-in-cardiology/articles/2016/06/13/10/01/ivus-in-pci-guidance>
38. Davies JE, Sen S, Dehbi HM, et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. *N Engl J Med.* May 11 2017;376(19):1824-1834. doi:10.1056/NEJMoa1700445
39. Götberg M, Christiansen EH, Gudmundsdottir IJ, et al. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. *N Engl J Med.* May 11 2017;376(19):1813-1823. doi:10.1056/NEJMoa1616540
40. Götberg M, Cook CM, Sen S, Nijjer S, Escaned J, Davies JE. The Evolving Future of Instantaneous Wave-Free Ratio and Fractional Flow Reserve. *J Am Coll Cardiol.* Sep 12 2017;70(11):1379-1402. doi:10.1016/j.jacc.2017.07.770
41. Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). *Eur Heart J.* Nov 2009;30(21):2631-71. doi:10.1093/eurheartj/ehp298

[McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Saji TT, Pahl E; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. *Circulation.* 2017 Apr 25;135\(17\):e927-e999. doi: 10.1161/CIR.0000000000000484. Epub 2017 Mar 29. Erratum in: *Circulation.* 2019 Jul 30;140\(5\):e181-e184. PMID: 28356445.](#)

ADDITIONAL RESOURCES:

1. ~~Doherty JU, Kort S, Mehran R, et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. *J Am Coll Cardiol*. Feb 5 2019;73(4):488-516. doi:10.1016/j.jacc.2018.10.038~~
2. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. Dec 21 2010;122(25):2748-64. doi:10.1161/CIR.0b013e3182051bab
3. Mark DB, Berman DS, Budoff MJ, et al. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. *J Am Coll Cardiol*. Jun 8 2010;55(23):2663-99. doi:10.1016/j.jacc.2009.11.013
4. Rybicki FJ, Udelson JE, Peacock WF, et al. 2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients With Chest Pain: A Joint Document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Appropriate Use Criteria Task Force. *J Am Coll Cardiol*. Feb 23 2016;67(7):853-79. doi:10.1016/j.jacc.2015.09.011
5. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Oct 15 2013;62(16):e147-239. doi:10.1016/j.jacc.2013.05.019

POLICY HISTORY

<u>Date</u>	<u>Summary</u>
<u>April 2023</u>	<ul style="list-style-type: none">• <u>Added Electrophysiology testing prior to ablation</u>• <u>Added Kawasaki/MIS-C section on follow up</u>• <u>Added statement about low pretest probability</u>• <u>Added statement on clinical indications not addressed in this guideline</u>
<u>February 2022</u>	<ul style="list-style-type: none">• <u>Clarified “intermediate lesions are 50-69%” for ischemia-producing disease</u>
<u>January 2022</u>	<p><u>[Off-cycle review]</u></p> <ul style="list-style-type: none">• <u>Deleted the requirement for stress echocardiography.</u>• <u>Changed to Intermediate and High probability chest pain patients now allowable as first line testing</u>• <u>Intermediate DTS patients now allowable for CCTA</u>• <u>Removed EF < 40%, keeping the existing EF < 50% systolic dysfunction, and adding symptomatic diastolic heart failure with no prior workup</u>• <u>Added a paragraph explaining the changes, new guidelines of November 2021 with contraindications within the overview section</u>• <u>Added section on when CCTA is preferred over ETT in low-risk patients</u>• <u>Deleted the phrasing ‘scenarios that support MPI over SE’ as it would no longer apply here. Replaced with ‘Scenarios that can additionally support a CCTA over a regular exercise treadmill test in the low probability scenario’.</u>• <u>Deleted statement that MPI may be supported over CCTA in Poorly controlled atrial fibrillation/ectopy</u>• <u>Took out the word ‘intermediate’ in the phrase “The (symptomatic) low pretest probability patient who is able to exercise and has an interpretable ECG”</u>• <u>Removed section on Coronary Artery calcium scoring</u>

Reviewed / Approved by NIA Clinical Guideline Committee

Disclaimer: *National Imaging Associates, Inc. (NIA) authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Evolent Health LLC subsidiaries including, but not limited to, National Imaging Associates (“NIA”). The policies constitute only the reimbursement and coverage guidelines of NIA. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. NIA reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.*

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.